PHASE II | AI has been helping life science companies study the effects of their new therapies prospectively in ‘enriched populations’.
The enrichment of a study population through the use of AI powered predictive analytics models to detect disease up to five years (before it develops), is enabling life science companies to investigate the effect of their novel treatments on “preventing the onset of disease” and or “halting/ slowing the progression” in early diagnosed disease patients.
When deployed in trial centers these AI solutions are expediting the identification of patients at risk of developing disease (enriched populations) whom are triaged to receive sponsor therapies to increase the likelihood of observing a treatment effect.
Contact us for further information
